Fig. 2From: The impact of mass drug administration on Schistosoma haematobium infection: what is required to achieve morbidity control and elimination?Age-intensity and age-prevalence cross-sectional profiles for Schistosoma haematobium in Tanzania (first row) and Kenya (second row) [18, 25]Back to article page